%PDF-1.6
%
1 0 obj
<>]/Pages 2 0 R/Type/Catalog>>
endobj
461 0 obj
<>stream
Adobe Acrobat 9.55 Paper Capture Plug-in
2017-11-10T14:12:06-05:00
2017-12-14T22:14:14-05:00
ScandAll PRO V1.8 Update1
2017-12-14T22:14:14-05:00
uuid:9ad0ea65-7acf-4e9f-be98-7a17a3f1c844
uuid:fa72483d-e1f7-4d1a-a1bf-1f06a753eda9
application/pdf
1
B
http://ns.adobe.com/pdf/1.3/
pdf
Adobe PDF Schema
internal
A name object indicating whether the document has been modified to include trapping information
Trapped
Text
http://ns.adobe.com/xap/1.0/mm/
xmpMM
XMP Media Management Schema
internal
UUID based identifier for specific incarnation of a document
InstanceID
URI
http://www.aiim.org/pdfa/ns/id/
pdfaid
PDF/A ID Schema
internal
Part of PDF/A standard
part
Integer
internal
Amendment of PDF/A standard
amd
Text
internal
Conformance level of PDF/A standard
conformance
Text
endstream
endobj
4198 0 obj
<>
endobj
2 0 obj
<>
endobj
172 0 obj
<>
endobj
171 0 obj
<>
endobj
253 0 obj
<>
endobj
334 0 obj
<>
endobj
415 0 obj
<>
endobj
347 0 obj
<>
endobj
363 0 obj
<>
endobj
379 0 obj
<>
endobj
395 0 obj
<>
endobj
411 0 obj
<>
endobj
428 0 obj
<>
endobj
444 0 obj
<>
endobj
460 0 obj
<>
endobj
441 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<>>>/Type/Page>>
endobj
445 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Type/Page>>
endobj
448 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Type/Page>>
endobj
451 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Type/Page>>
endobj
454 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Type/Page>>
endobj
457 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC]/XObject<>>>/Type/Page>>
endobj
4205 0 obj
<>stream
BT
/CS0 cs 0.227 0.216 0.223 scn
/T1_0 1 Tf
-0.0047 Tc 3 Tr 11.5 0 0 11.5 525.92 745.45 Tm
(129 )Tj
0.0004 Tc -35.742 -3.11 Td
(251. )Tj
0.0008 Tc 2.492 0 Td
(Sun, )Tj
0.0102 Tc 2.393 0 Td
(H., )Tj
0.0302 Tc 1.81 0 Td
(et )Tj
-0.0065 Tc 1.315 0 Td
(al., )Tj
/T1_1 1 Tf
0.0014 Tc 12 0 0 12 227.62 709.68 Tm
(KPT-330 )Tj
0.0039 Tc 4.226 0 Td
(has )Tj
0.003 Tc 1.919 0 Td
(antitumour )Tj
-0.0012 Tc 5 0 Td
(activity )Tj
0.0043 Tc 3.44 0 Td
(against )Tj
-0.0002 Tc 3.482 0 Td
(non-small )Tj
-0.0022 Tc 4.517 0 Td
(cell )Tj
0.0023 Tc 1.937 0 Td
(lung )Tj
-0.0049 Tc -31.557 -1.159 Td
(cancer)Tj
0.361 0.365 0.372 scn
0 Tc 2.697 0 Td
(. )Tj
0.227 0.216 0.223 scn
/T1_0 1 Tf
0.0235 Tc 11.5 0 0 11.5 181.87 695.77 Tm
(British )Tj
0.033 Tc 3.033 0 Td
(journal )Tj
0.05 Tc 12.7985 0 0 11.5 254.52 695.77 Tm
(of )Tj
0.0179 Tc 11.5 0 0 11.5 267.73 695.77 Tm
(cancer, )Tj
0.04 Tc 3.259 0 Td
(2014.111\(2\): )Tj
-0.0106 Tc 5.956 0 Td
(p. )Tj
0.0096 Tc 1.077 0 Td
(281-291. )Tj
0.0004 Tc -23.583 -2.797 Td
(252. )Tj
0.0147 Tc 2.464 0 Td
(Mutka, )Tj
0.0113 Tc 3.68 0 Td
(S.C., )Tj
0.0302 Tc 2.742 0 Td
(et )Tj
0.0005 Tc 1.44 0 Td
(al., )Tj
/T1_1 1 Tf
0.0021 Tc 12 0 0 12 256.2 663.6 Tm
(Identification )Tj
0.05 Tc 13.9795 0 0 12 329.64 663.6 Tm
(of )Tj
0.004 Tc 12 0 0 12 346.74 663.6 Tm
(nuc/ear )Tj
0.0043 Tc 3.716 0 Td
(export )Tj
-0.0032 Tc 3.237 0 Td
(inhibitors )Tj
-0.0045 Tc 4.527 0 Td
(with )Tj
0.0236 Tc 2.278 0 Td
(potent )Tj
-0.0004 Tc -30.72 -1.179 Td
(anticancer )Tj
-0.0012 Tc 4.52 0 Td
(activity )Tj
-0.035 Tc 11.9167 0 0 12 236.01 649.45 Tm
(in )Tj
-0.0315 Tc 12 0 0 12 248.09 649.45 Tm
(vivo. )Tj
/T1_0 1 Tf
0.0231 Tc 11.5 0 0 11.5 274.68 649.45 Tm
(Cancer )Tj
0.0226 Tc 3.202 0 Td
(research)Tj
0.361 0.365 0.372 scn
0 Tc 3.492 0 Td
(, )Tj
0.227 0.216 0.223 scn
0.0397 Tc 0.51 0 Td
(2009.69\(2\): )Tj
-0.0106 Tc 5.413 0 Td
(p. )Tj
0.0088 Tc 1.09 0 Td
(510-517. )Tj
0.0004 Tc -27.603 -2.776 Td
(253. )Tj
0.0226 Tc 2.443 0 Td
(Plafker)Tj
0.361 0.365 0.372 scn
0 Tc 3.036 0 Td
(, )Tj
0.227 0.216 0.223 scn
/T1_2 1 Tf
0.0026 Tc 11.7 0 0 11.7 187.91 617.53 Tm
(K. )Tj
/T1_0 1 Tf
0.0249 Tc 11.5 0 0 11.5 207.24 617.53 Tm
(and )Tj
-0.0056 Tc 2.174 0 Td
(I.G. )Tj
0.0176 Tc 2.277 0 Td
(Macara, )Tj
/T1_1 1 Tf
0.0074 Tc 12 0 0 12 304.89 617.53 Tm
(Facilitated )Tj
-0.0011 Tc 5.048 0 Td
(nuc/eocytoplasmic )Tj
0.006 Tc 8.028 0 Td
(shuttling )Tj
0.05 Tc 14.2769 0 0 12 511.56 617.53 Tm
(of )Tj
-0.035 Tc 11.9593 0 0 12 528.34 617.53 Tm
(the )Tj
-0.0035 Tc 12 0 0 12 142.89 603.6 Tm
(Ran )Tj
0.0045 Tc 2.205 0 Td
(binding )Tj
0.0115 Tc 3.541 0 Td
(protein )Tj
0.0082 Tc 3.514 0 Td
(RanBP )Tj
/T1_0 1 Tf
0 Tc 11.5 0 0 11.5 288.32 603.6 Tm
(1)Tj
0.361 0.365 0.372 scn
0.515 0 Td
(. )Tj
0.227 0.216 0.223 scn
0.0256 Tc 0.872 0 Td
(Molecular )Tj
0.0249 Tc 4.898 0 Td
(and )Tj
0.0165 Tc 2.109 0 Td
(cellular )Tj
0.0124 Tc 3.704 0 Td
(biology, )Tj
0.0005 Tc 4.042 0 Td
(2000. )Tj
0.0031 Tc 2.943 0 Td
(20\(10\): )Tj
0.0396 Tc -31.714 -1.21 Td
(p.3510-3521. )Tj
0.0004 Tc -2.45 -2.796 Td
(254. )Tj
0.0222 Tc 2.41 0 Td
(Niu, )Tj
0.0099 Tc 2.141 0 Td
(M., )Tj
0.0093 Tc 1.747 0 Td
(et )Tj
0.0005 Tc 1.023 0 Td
(al., )Tj
/T1_1 1 Tf
-0.0332 Tc 12 0 0 12 217.2 557.53 Tm
(CRM1 )Tj
-0.029 Tc 2.908 0 Td
(is )Tj
0 Tc 0.946 0 Td
(a )Tj
0.0011 Tc 0.759 0 Td
(cellular )Tj
0.004 Tc 3.396 0 Td
(target )Tj
0.05 Tc 14.2769 0 0 12 345.24 557.53 Tm
(of )Tj
-0.0058 Tc 12 0 0 12 357.99 557.53 Tm
(curcumin)Tj
0.361 0.365 0.372 scn
0 Tc 3.79 0 Td
(: )Tj
0.227 0.216 0.223 scn
-0.0164 Tc 0.592 0 Td
(new )Tj
-0.0017 Tc 1.892 0 Td
(insights )Tj
0.0318 Tc 3.245 0 Td
(for )Tj
-0.0269 Tc 1.576 0 Td
(the )Tj
0.0053 Tc 1.507 0 Td
(myriad )Tj
0.0229 Tc -30.503 -1.161 Td
(ofbiological )Tj
-0.0026 Tc 5.339 0 Td
(effects )Tj
0.05 Tc 14.2769 0 0 12 240.84 543.6 Tm
(of )Tj
-0.0112 Tc 12 0 0 12 253.12 543.6 Tm
(an )Tj
0.0081 Tc 1.26 0 Td
(ancient )Tj
-0.0068 Tc 3.21 0 Td
(spice)Tj
0.361 0.365 0.372 scn
0 Tc 2.047 0 Td
(. )Tj
0.227 0.216 0.223 scn
/T1_0 1 Tf
0.0119 Tc 11.5 0 0 11.5 337.58 543.6 Tm
(Traffic, )Tj
0.0362 Tc 3.425 0 Td
(2013.14\(10\): )Tj
-0.0106 Tc 5.914 0 Td
(p. )Tj
0.0112 Tc 1.132 0 Td
(1042-1052. )Tj
0.0004 Tc -29.836 -2.796 Td
(255. )Tj
0.0214 Tc 2.41 0 Td
(Naniwa, )Tj
-0.0022 Tc 4.33 0 Td
(J., )Tj
0.0302 Tc 1.707 0 Td
(et )Tj
0.0005 Tc 1.544 0 Td
(al., )Tj
/T1_1 1 Tf
0.0044 Tc 12 0 0 12 253.32 511.45 Tm
(Leptomycin )Tj
0 Tc 5.437 0 Td
(B )Tj
-0.0035 Tc 1.403 0 Td
(enhances )Tj
-0.001 Tc 4.489 0 Td
(CDDP-sensitivity )Tj
-0.0066 Tc 7.774 0 Td
(via )Tj
-0.006 Tc 1.981 0 Td
(nuc/ear )Tj
-0.0009 Tc -30.282 -1.161 Td
(accumulation )Tj
0.05 Tc 14.2769 0 0 12 212.28 497.52 Tm
(of )Tj
0.0274 Tc 12 0 0 12 224.32 497.52 Tm
(p53 )Tj
0.0148 Tc 1.82 0 Td
(protein )Tj
-0.035 Tc 11.9167 0 0 12 286.17 497.52 Tm
(in )Tj
-0.0032 Tc 12 0 0 12 299.14 497.52 Tm
(HPV-positive )Tj
-0.0039 Tc 5.744 0 Td
(cells)Tj
0.361 0.365 0.372 scn
0 Tc 1.817 0 Td
(. )Tj
0.227 0.216 0.223 scn
/T1_0 1 Tf
0.0189 Tc 11.5 0 0 11.5 397.08 497.52 Tm
(Cancer )Tj
0.0133 Tc 3.273 0 Td
(science, )Tj
0.0057 Tc 3.66 0 Td
(2003. )Tj
0.0006 Tc 2.687 0 Td
(94\(12\): )Tj
-0.0314 Tc -31.73 -1.21 Td
(p. )Tj
0.0112 Tc 1.133 0 Td
(1099-1103. )Tj
-0.0066 Tc -3.561 -2.777 Td
(256. )Tj
0.017 Tc 2.425 0 Td
(Asselin, )Tj
0.0045 Tc 3.71 0 Td
(E., )Tj
-0.0052 Tc 1.477 0 Td
(G.B. )Tj
0.0187 Tc 2.239 0 Td
(Mills, )Tj
0.0353 Tc 2.79 0 Td
(and )Tj
0.0109 Tc 1.822 0 Td
(B.K. )Tj
0.0117 Tc 2.291 0 Td
(Tsang, )Tj
/T1_1 1 Tf
0.006 Tc 12 0 0 12 342.73 451.68 Tm
(XIAP )Tj
-0.0021 Tc 2.513 0 Td
(regulates )Tj
0.0474 Tc 3.961 0 Td
(Akt )Tj
0.0017 Tc 1.678 0 Td
(activity )Tj
0.0344 Tc 3.22 0 Td
(and )Tj
-0.0091 Tc 1.799 0 Td
(caspase-)Tj
0.0045 Tc -29.822 -1.159 Td
(3-dependent )Tj
-0.0051 Tc 5.622 0 Td
(c/eavage )Tj
0.0035 Tc 4.242 0 Td
(during )Tj
0.0048 Tc 3.378 0 Td
(cisplatin-induced )Tj
-0.0004 Tc 7.621 0 Td
(apoptosis )Tj
-0.035 Tc 11.9167 0 0 12 447.69 437.77 Tm
(in )Tj
-0.0063 Tc 12 0 0 12 465.05 437.77 Tm
(human )Tj
-0.0148 Tc 3.398 0 Td
(ovarian )Tj
0.0003 Tc -30.241 -1.16 Td
(epithelial )Tj
-0.0049 Tc 4.042 0 Td
(cancer )Tj
-0.0129 Tc 2.96 0 Td
(ce/Is)Tj
0.361 0.365 0.372 scn
0 Tc 1.837 0 Td
(. )Tj
0.227 0.216 0.223 scn
/T1_0 1 Tf
0.0231 Tc 11.5 0 0 11.5 255.24 423.85 Tm
(Cancer )Tj
0.0147 Tc 3.223 0 Td
(research, )Tj
0.0109 Tc 4.002 0 Td
(2001. )Tj
0.0047 Tc 2.623 0 Td
(61\(5\): )Tj
-0.0106 Tc 2.79 0 Td
(p. )Tj
0.0089 Tc 1.132 0 Td
(1862-1868. )Tj
0.0004 Tc -25.996 -2.797 Td
(257. )Tj
0.0078 Tc 2.492 0 Td
(Shu, )Tj
0.0203 Tc 2.521 0 Td
(X.-R., )Tj
0.0302 Tc 3.289 0 Td
(et )Tj
0.0005 Tc 1.44 0 Td
(al., )Tj
/T1_1 1 Tf
0.0012 Tc 12 0 0 12 249.21 391.68 Tm
(PAK4 )Tj
-0.0013 Tc 3.085 0 Td
(confers )Tj
-0.0269 Tc 3.596 0 Td
(the )Tj
-0.005 Tc 1.887 0 Td
(malignance )Tj
0.05 Tc 13.9795 0 0 12 415.8 391.68 Tm
(of )Tj
-0.0002 Tc 12 0 0 12 433.11 391.68 Tm
(cervical )Tj
-0.0023 Tc 3.86 0 Td
(cancers )Tj
0.0144 Tc 3.761 0 Td
(and )Tj
-0.0002 Tc -31.801 -1.159 Td
(contributes )Tj
-0.035 Tc 11.7411 0 0 12 203.62 377.77 Tm
(to )Tj
-0.0169 Tc 12 0 0 12 219.46 377.77 Tm
(the )Tj
0.0006 Tc 1.784 0 Td
(cisplatin-resistance )Tj
-0.035 Tc 11.9167 0 0 12 342.09 377.77 Tm
(in )Tj
-0.0002 Tc 12 0 0 12 357.99 377.77 Tm
(cervical )Tj
-0.0009 Tc 3.74 0 Td
(cancer )Tj
-0.0039 Tc 3.28 0 Td
(cells )Tj
-0.0066 Tc 2.382 0 Td
(via )Tj
-0.035 Tc 11.9548 0 0 12 491.61 377.77 Tm
(PJ3K1AKT )Tj
0.0148 Tc 12 0 0 12 142 363.85 Tm
(pathway)Tj
0.361 0.365 0.372 scn
0 Tc 3.457 0 Td
(. )Tj
0.227 0.216 0.223 scn
/T1_0 1 Tf
0.0195 Tc 11.5 0 0 11.5 189.55 363.85 Tm
(Diagnostic )Tj
0.0184 Tc 4.764 0 Td
(pathology, )Tj
0.0397 Tc 4.73 0 Td
(2015.10\(1\): )Tj
-0.0106 Tc 5.413 0 Td
(p. )Tj
-0.035 Tc 10.8143 0 0 11.5 374.02 363.85 Tm
(1. )Tj
0.0004 Tc 11.5 0 0 11.5 114.65 331.93 Tm
(258. )Tj
0.0102 Tc 2.444 0 Td
(Zou, )Tj
0.0018 Tc 2.212 0 Td
(W., )Tj
0.0302 Tc 1.767 0 Td
(et )Tj
0.0075 Tc 1.002 0 Td
(al., )Tj
/T1_1 1 Tf
-0.0077 Tc 12 0 0 12 217.92 331.93 Tm
(Caveolin-1 )Tj
0.0009 Tc 4.715 0 Td
(mediates )Tj
-0.0018 Tc 3.817 0 Td
(chemoresistance )Tj
-0.035 Tc 11.9167 0 0 12 403.53 331.93 Tm
(in )Tj
0.0022 Tc 12 0 0 12 415.59 331.93 Tm
(cisplatin-resistant )Tj
-0.0081 Tc 7.479 0 Td
(ovarian )Tj
-0.0049 Tc -30.199 -1.161 Td
(cancer )Tj
-0.0039 Tc 3.26 0 Td
(cells )Tj
-0.0021 Tc 2.4 0 Td
(by )Tj
0.0029 Tc 1.496 0 Td
(targeting )Tj
0.0021 Tc 4.225 0 Td
(apoptosis )Tj
-0.0033 Tc 4.415 0 Td
(through )Tj
-0.0269 Tc 3.74 0 Td
(the )Tj
-0.0159 Tc 1.741 0 Td
(Notch-1)Tj
0.361 0.365 0.372 scn
0 Tc 3.202 0 Td
(/)Tj
0.227 0.216 0.223 scn
0.05 Tc 12.1244 0 0 12 439.86 318 Tm
(Akt)Tj
0.361 0.365 0.372 scn
0 Tc 12 0 0 12 456.13 318 Tm
(/)Tj
0.227 0.216 0.223 scn
-0.035 Tc 11.7346 0 0 12 459.7 318 Tm
(NF-KB )Tj
-0.0116 Tc 12 0 0 12 498.16 318 Tm
(pathway. )Tj
/T1_0 1 Tf
0.0214 Tc 11.5 0 0 11.5 142.92 303.85 Tm
(Oncology )Tj
0.0121 Tc 4.35 0 Td
(reports, )Tj
0.0057 Tc 3.439 0 Td
(2015. )Tj
0.0113 Tc 2.603 0 Td
(34\(6\): )Tj
-0.0106 Tc 2.81 0 Td
(p. )Tj
0.0143 Tc 1.093 0 Td
(3256-3263. )Tj
0.0004 Tc -16.774 -2.776 Td
(259. )Tj
0.0071 Tc 2.464 0 Td
(Fan, )Tj
-0.0021 Tc 2.214 0 Td
(Y., )Tj
0.0302 Tc 1.641 0 Td
(et )Tj
0.0005 Tc 1.148 0 Td
(al., )Tj
/T1_1 1 Tf
-0.0018 Tc 12 0 0 12 219.21 271.93 Tm
(Rab25 )Tj
-0.029 Tc 3.02 0 Td
(is )Tj
-0.0026 Tc 1.027 0 Td
(responsible )Tj
0.0218 Tc 4.878 0 Td
(for )Tj
0.0044 Tc 1.561 0 Td
(phosphoinositide )Tj
-0.003 Tc 7.298 0 Td
(3-kinase)Tj
0.361 0.365 0.372 scn
0 Tc 3.34 0 Td
(/)Tj
0.227 0.216 0.223 scn
0.0091 Tc 0.264 0 Td
(AKTmediated )Tj
-0.0033 Tc -27.762 -1.161 Td
(cisplatin )Tj
-0.0054 Tc 3.722 0 Td
(resistance )Tj
-0.035 Tc 11.9167 0 0 12 239.61 258 Tm
(in )Tj
-0.0063 Tc 12 0 0 12 252.17 258 Tm
(human )Tj
0.0025 Tc 2.997 0 Td
(epithelial )Tj
-0.0015 Tc 4.041 0 Td
(ovarian )Tj
-0.0049 Tc 3.401 0 Td
(cancer )Tj
-0.0179 Tc 2.98 0 Td
(ce/Is)Tj
0.361 0.365 0.372 scn
0 Tc 1.817 0 Td
(. )Tj
0.227 0.216 0.223 scn
/T1_0 1 Tf
0.0279 Tc 11.5 0 0 11.5 441.55 258 Tm
(Mol )Tj
0.0388 Tc 2.024 0 Td
(Med )Tj
0.0072 Tc 2.191 0 Td
(Rep, )Tj
0.0005 Tc 2.211 0 Td
(2015. )Tj
0.0057 Tc -32.397 -1.21 Td
(11\(3\): )Tj
-0.0314 Tc 2.77 0 Td
(p. )Tj
0.0145 Tc 1.057 0 Td
(2173-8. )Tj
ET
q
7.6799927 0 0 399.3600006 0 391.4160004 cm
/Im0 Do
Q
q
11.5200043 0 0 372.4799957 0 18.9360046 cm
/Im1 Do
Q
q
/CS0 cs 0.159 0.159 0.159 scn
433.9199982 0 0 518.3999939 111.3600006 237.8159943 cm
/Im2 Do
Q
endstream
endobj
3548 0 obj
<>stream
Adobe d
$''''$25552;;;;;;;;;;
$$22;222;;;;;;;;;;;;;;;;@@@@;;;@@@@@;@@@@@@@@@@@@@@@@@@@@@ @ B
3 !1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw ; !1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ? v$3O["Jy6$G[?RSu/9%=60j[D=KmIOOoIO1Կ 2%